OsoBio Honored for Corporate Efforts to Protect Integrity of Rio Grande

OsoBio Honored for Corporate Efforts to Protect Integrity of Rio Grande

OSO BioPharmaceuticals Manufacturing, LLC, has received the Pollution Prevention Award for its efforts to protect water quality in the Rio Grande River - OsoBio.com.
 
   
  The honor was awarded by the Albuquerque Bernalillo County Water Utility as part of its Pollution Prevention Program (P2 Program).

The P2 Program was created in 1992 to protect Albuquerque's water treatment plant and the Rio Grande River from harmful waste runoff. The program recognizes businesses for reducing or eliminating the creation of pollutants at their source through equipment and process modifications, reformulation or redesign of products, substitution of raw materials, and improvements in housekeeping, maintenance, training or inventory control that results in reduced waste generation.

In OsoBio's case, the company implemented changes to its raw materials processes, which reduced wastewater by 25 percent. The company also installed a state-of-the-art treatment system that improved the quality of water discharged from its facilities.

"OsoBio prides itself on being a conscientious corporate citizen in Albuquerque, which includes respecting the sensitive environment we share with our neighbors and doing our part to protect it from further degradation," said Dr. Stuart Rose, president and CEO. "It is gratifying to know that by reducing OsoBio's environmental footprint, we are making a positive contribution to our community."

OsoBio (osobio.com) is a contract manufacturing organization focusing on biologic and pharmaceutical injectables. Headquartered in Albuquerque, N.M., OsoBio specializes in products that require complex handling, including highly potent compounds.

OsoBio surpasses quality-assurance expectations within our industry. Our employees are industry veterans who provide innovative solutions to our clients' most difficult projects.
 
  

Suggested Articles

BMS’s Opdivo has plenty of competition in its current bladder cancer indication—so it’s hoping to strike out on its own in a new area of the disease.

The Japanese approval, under the brand name Jyseleca, came a month after an FDA complete response letter that asked Gilead for more data.

The Trump Administration has opened the doors for Florida and other states to import prescription drugs from Canada—despite industry objections.